Clinical Trial: Randomized Phase II Trial Evaluating the Induction Therapy of PTX+BV Followed by Atezolizumab+nab-PTX for PD-L1+ TNBC

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793553) titled 'Randomized Phase II Trial Evaluating the Induction Therapy of PTX+BV Followed by Atezolizumab+nab-PTX for PD-L1+ TNBC' on Jan. 21.

Brief Summary: The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.

Study Start Date: Sept. 13, 2024

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer ...